

## **DISEASE BURDEN**



In 2023, 39.9 million people globally were living with HIV, 1.3 million people became newly infected, and 630,000 people died of HIV, most of which occurred in LMICs.



## CLINICAL RELEVANCE



This formulation is also investigated for the HIV treatment indication. A phase III trial of cabotegravir 4-monthly with rilpivirine 4-monthly is planned following successful phase I results.





## **SERVICE DELIVERY ENABLERS**

Cabotegravir ultra long-acting's possible companion drugs for a fully long-acting treatment regimen are still under study. While cabotegravir 4-monthly may have advantages in terms of adherence, health system requirements for delivery might be higher compared compared to once-daily oral treatment options such as TLD that can be handed to people needing the treatment for several months courses. Similar considerations apply to a PrEP indication as a single agent.





Primary patents on cabotegravir have been granted in many LMICs and are expected to expire in 2026. A secondary patent on the 4-monthly formulation was published in March 2025. The corresponding international patent application is pending, and geographical coverage in LMICs is expected to be available by March 2026, with patents anticipated to expire in 2043.

